Lantern Pharma Inc.
Index- P/E- EPS (ttm)-1.32 Insider Own23.35% Shs Outstand10.84M Perf Week2.09%
Market Cap52.27M Forward P/E- EPS next Y-1.88 Insider Trans-21.06% Shs Float8.32M Perf Month-14.77%
Income-14.40M PEG- EPS next Q-0.47 Inst Own30.60% Short Float / Ratio1.71% / 3.65 Perf Quarter-19.08%
Sales- P/S- EPS this Y-19.40% Inst Trans0.88% Short Interest0.14M Perf Half Y-7.47%
Book/sh5.45 P/B0.85 EPS next Y-27.00% ROA-21.30% Target Price13.00 Perf Year-33.26%
Cash/sh5.15 P/C0.90 EPS next 5Y- ROE-22.40% 52W Range4.05 - 7.92 Perf YTD-23.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.35% Beta-
Dividend %- Quick Ratio19.80 Sales past 5Y- Gross Margin- 52W Low14.69% ATR0.37
Employees14 Current Ratio19.80 Sales Q/Q- Oper. Margin- RSI (14)40.82 Volatility6.42% 7.50%
OptionableYes Debt/Eq0.00 EPS Q/Q42.30% Profit Margin- Rel Volume1.27 Prev Close4.65
ShortableYes LT Debt/Eq0.00 EarningsMar 20 AMC Payout- Avg Volume39.03K Price4.64
Recom2.00 SMA20-8.17% SMA50-12.97% SMA200-11.53% Volume7,662 Change-0.11%
Oct-07-21Initiated H.C. Wainwright Buy $32
Mar-20-23 04:01PM
Mar-15-23 08:00AM
Mar-13-23 08:00AM
08:00AM Loading…
Mar-09-23 08:00AM
Mar-08-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-27-23 08:00AM
Feb-21-23 12:10PM
Feb-15-23 08:00AM
Feb-01-23 04:55AM
Jan-17-23 08:00AM
Jan-05-23 08:59AM
06:15AM Loading…
Dec-31-22 06:15AM
Dec-15-22 08:00AM
Dec-13-22 08:00AM
Dec-02-22 01:46PM
Nov-22-22 08:00AM
Nov-08-22 04:48AM
Nov-07-22 04:01PM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-25-22 08:00AM
Oct-21-22 07:00AM
Oct-20-22 07:59AM
Oct-13-22 10:48AM
Oct-11-22 04:00PM
08:00AM Loading…
Oct-05-22 08:00AM
Sep-23-22 08:50AM
Sep-19-22 08:50AM
Sep-14-22 12:05PM
Aug-30-22 09:00AM
Aug-19-22 08:30AM
Aug-09-22 08:20AM
Aug-08-22 04:01PM
Aug-01-22 07:00AM
Jul-14-22 07:00AM
May-12-22 07:00AM
May-06-22 10:29AM
May-05-22 08:00AM
May-03-22 04:01PM
Apr-26-22 07:15AM
Apr-22-22 07:00AM
Apr-14-22 11:10AM
Mar-22-22 07:00AM
Mar-14-22 07:00AM
Mar-10-22 04:05PM
Mar-03-22 07:00AM
Feb-15-22 06:59AM
Feb-02-22 05:38PM
Jan-26-22 04:30PM
Jan-24-22 07:00AM
Jan-20-22 08:04AM
Jan-18-22 06:30AM
Jan-12-22 06:03AM
Jan-04-22 09:29AM
Dec-14-21 09:01AM
Nov-22-21 09:00AM
Nov-12-21 09:40AM
Nov-11-21 09:15AM
Nov-09-21 09:00AM
Nov-08-21 08:44AM
Nov-04-21 09:37AM
Nov-03-21 09:41AM
Nov-01-21 04:05PM
Oct-27-21 09:05AM
Oct-25-21 04:57PM
Oct-04-21 04:30PM
Sep-30-21 09:00AM
Sep-28-21 09:20AM
Sep-22-21 09:00AM
Sep-07-21 09:00AM
Sep-02-21 08:59AM
Aug-30-21 08:59AM
Aug-19-21 03:15PM
Aug-16-21 08:20AM
Aug-11-21 08:21AM
Aug-09-21 05:42AM
Aug-05-21 06:21AM
Jul-29-21 04:01PM
Jul-27-21 08:00AM
Jul-22-21 04:08PM
Jul-20-21 08:12AM
Jun-13-21 10:30PM
May-25-21 08:14AM
May-17-21 08:55AM
May-12-21 07:45AM
May-10-21 06:35AM
May-03-21 04:32PM
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kreis Leslie W.10% OwnerNov 08Sale4.40350,0001,540,00071,774Nov 09 09:39 PM
Fletcher Aaron G.L.10% OwnerNov 08Sale4.40350,0001,540,00071,774Nov 09 09:37 PM
Kreis Leslie W.10% OwnerSep 02Sale5.206,44533,51420,930Sep 07 04:54 PM
Fletcher Aaron G.L.10% OwnerSep 02Sale5.206,44533,51420,930Sep 07 04:55 PM